Researchers routinely misread the four IRB review pathways, and that misreading costs them time. The gap between what sponsors assume and what regulators require shows up most clearly in processing times: at UNC, full board initial review averaged 58 days in 2025, versus 21 days for expedited and 12 for exempt. Submitting a protocol to the wrong pathway, or submitting one that is under-documented for full board, can push a study weeks past its target start date before the first participant is even screened.
The most persistent error is treating “minimal risk” as a synonym for “exempt.” Exemptions are not a risk threshold; they are a checklist of specific regulatory categories listed in 45 CFR 46.104. A benign survey that involves minors may fail an exemption category written for adults, regardless of how little risk the survey poses. Conversely, a minimal-risk study can end up requiring full board review simply because none of its procedures fit any category eligible for expedited handling. The two questions are separate, and collapsing them is what sends otherwise straightforward protocols into avoidable review cycles.
The word “expedited” creates its own confusion. It describes who reviews the study, not how fast the decision arrives. A single designated board member can act without waiting for a convened meeting, but questions or missing documentation extend the process just as they would at full board. Eligibility also requires two conditions to hold simultaneously: the study must be minimal risk, and every procedure must map to a recognized expedited category. Collecting skin cells by swab, for example, can qualify under noninvasive specimen collection; a punch biopsy cannot. One procedure mismatch shifts the entire study.
The NHSR determination adds another layer researchers frequently skip. Under HHS rules, activity that does not constitute a systematic investigation designed to generate generalizable knowledge may not be research at all, making any review category irrelevant. FDA-regulated research follows a different logic: identifiability of samples is not determinative the way it is under HHS, so a project that looks like NHSR under one framework may require full IRB consideration under the other. Getting that framework question answered before selecting a review pathway is the step most likely to prevent a protocol from cycling back to the start. The practical marker to watch is whether the protocol specifies which regulatory framework applies; if it does not, the IRB will ask, and the clock will not move until it does.
Source link: https://www.advarra.com/blog/nhsr-exempt-expedited-or-full-board-a-plain-language-guide-to-potential-review-pathways/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
